

PRODUCT DISRUPTION BRIEF

ICU Medical- MS5400 Portex Arterial Blood Sampling

(May 22, 2026)

Current conditions

ICU Medical has reported a temporary supply shortage affecting its Pro-Vent™ and LineDraw™ arterial blood sampling product lines. The disruption is attributable to a heparin supply constraint, which reduced planned inventory levels during the transfer of manufacturing operations to the company’s facility in Southington, Connecticut. Although the site transition is expected to enhance long-term production capacity and quality, it has temporarily reduced manufacturing output. To mitigate the impact, the company has implemented additional production shifts, expanded staffing and engineering support, increased supply chain oversight, and prioritized select SKUs. Certain products experiencing the greatest disruption have also been placed on allocation to support equitable distribution of available inventory among customers.

Product Line	In Production	Status Update
3 mL Pro-Vent and LineDraw	Yes	U.S. manufacturing output is exceeding historical demand levels currently. While additional time is required to fully recover, meaningful improvements in product availability have already been achieved.
1 mL LineDraw and Pro-Vent	Yes	<p>Manufacturing began at the new site in March, and output is expected to meet U.S. historical monthly demand as follows:</p> <ul style="list-style-type: none"> • 1 mL LineDraw – May 2026 • 1 mL Pro-Vent – June 2026 <p>Each is expected to consistently ramp up ahead of historical demand levels</p>

Access the ICU Medical customer letter and alternative products list [here](#)

Clinical Alternatives

If clinical mitigation strategies become necessary, a venous blood gas (VBG) syringe can be used for most clinical situations involving assessment of acid–base status, ventilation, and metabolic disturbances, as VBG values for pH, CO₂, bicarbonate, and lactate closely correlate with ABG results and are reliable for trending in conditions such as diabetic ketoacidosis, sepsis, and other metabolic abnormalities. However, VBGs are not appropriate for evaluating oxygenation, as venous oxygen values do not accurately reflect arterial oxygen status.

As a last resort, manual heparinization of a syringe may be used in place of a pre-heparinized ABG syringe. This is performed by coating the syringe with heparin to prevent clotting; however, this method introduces increased risk of error, including improper heparin concentration, sample dilution, and potential impact on measured values. Proper education and strict adherence to technique are essential to ensure accurate results.

In all clinical practices, Vizient recommends accessing individual facility policies and procedures and adhering to best practice guidelines.



To learn more, please contact:
Courtney Jones, Category Manager
courtney.jones@vizientinc.com

As the nation’s largest member-driven health care performance improvement company, Vizient provides solutions and services that empower health care providers to deliver high-value care by aligning cost, quality and market performance. With analytics, advisory services and a robust sourcing portfolio, we help members improve patient outcomes and lower costs.

Disclaimer: The information contained in this document is intended for informational purposes only and is in no way intended to be a substitute for or in any manner to be construed as medical or clinical advice. The authors, editors, reviewers, contributors and publishers cannot be held responsible for the accuracy or continued accuracy of the information or for any errors or omissions in the document or for any consequences in the form of liability, loss, injury, or damage incurred as a result of the use and application of any of the information, either directly or indirectly.

[Supply assurance webpage](#); [Vizient Newsroom](#)



Want to receive weekly Supply Assurance updates?

Update your preferences through our [Subscription Manager](#) by selecting Supply Assurance Weekly Digest.

Questions? Contact disasterresponse@vizientinc.com, pharmacyquestions@vizientinc.com, novaplus@vizientinc.com.